Sofia, Bulgaria – Sopharma AD has announced the sale of 380 treasury shares on July 23, 2025. The transaction was conducted on the Bulgarian Stock Exchange with a total value of BGN 934.80, averaging BGN 2.46 per share.
Following this sale, the company retains a total of 8,365,347 treasury shares, which constitute 4.65% of its share capital.
“Sopharma” AD operates under regulations outlined in art. 17 of Regulation (EU) No 596/2014 by the European Parliament and Council.
Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…
The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.
Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…
Sign-up for the Weekly Newsletter from EU Business Daily.